IgGenix
IgGenix is a clinical-stage biotechnology company developing first-in-class human IgG4 monoclonal antibody therapeutics for IgE-mediated allergic diseases, using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform to discover allergen-blocking antibodies from allergic patients.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What IgGenix does
IgGenix, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered at Lilly Gateway Labs in South San Francisco, California. The company develops antibody therapeutics for IgE-mediated allergic diseases using its proprietary SEQ SIFTER™ platform—a single-cell RNA-sequencing-based discovery technology that captures extremely rare human B cells producing IgE antibodies directly from patient blood and re-engineers them into fully human, high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. IgGenix's lead product candidate is IGNX001, a first-in-class human IgG4 monoclonal antibody for peanut allergy that completed Phase 1 enrollment in September 2025. The broader pipeline targets additional food allergies (egg, fish, milk, sesame, shellfish, soy, tree nuts, wheat), environmental allergies (cat, dog, dust, mold, pollen), atopic dermatitis, and alpha-gal syndrome.
The company has raised approximately $75 million in venture capital across three funding rounds (Series A $10M in 2020, Series A1 $25M in 2021, Series B $40M in 2023) from investors including Khosla Ventures, Alexandria Venture Investments, Eli Lilly and Company, Prosperity Capital Management, Sean Parker, AllerFund, ShangBay Capital, Global Brain, and Parker Ventures. IgGenix operates an exclusive license from CZ Biohub SF, LLC to foundational patent No. 11,613,569 covering allergen-specific antibody generation methods. The business model is pharmaceutical therapeutic development: future revenue is expected to derive from commercialization of approved antibody products via traditional pharmaceutical channels (physician prescribing, specialty pharmacy distribution), though no products are yet approved and no pricing has been disclosed. Customer segments target both pediatric and adult allergy patients across food and environmental allergies, with a horizontal segmentation approach addressing multiple allergen categories.
IgGenix firmographics
Firmographics- Name
- IgGenix
- Legal name
- IgGenix, Inc.
- Website
- https://iggenix.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- IgGenix is a clinical-stage biotechnology company developing first-in-class human IgG4 monoclonal antibody therapeutics for IgE-mediated allergic diseases, using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform to discover allergen-blocking antibodies from allergic patients.
- Ownership category
- akta.pro rank
IgGenix industry classification
Industry- Product category
- Allergy Biologics / Antibody Therapeutics
- akta.pro primary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
- akta.pro secondary industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where IgGenix is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
IgGenix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Therapeutic Drug Development and Commercialization: IgGenix is developing antibody therapeutics for allergic diseases. As a clinical-stage biotechnology company, revenue will be generated through the commercialization of approved therapeutic products, initially targeting peanut allergy with IGNX001, and subsequently expanding to other food and environmental allergies.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
IgGenix product offering
Product offeringCore offering
IgGenix is a clinical-stage biotechnology company developing antibody therapeutics for allergic diseases. Using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform, the company isolates rare human IgE-producing B cells and re-engineers them into high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and is currently in Phase 1 clinical trials.
Product overview
IgGenix is a clinical-stage antibody discovery and development company with a pipeline focused on IgE-mediated allergic diseases. The company's core technology is the SEQ SIFTER™ platform, a single-cell RNA-sequencing-based discovery platform that isolates and re-engineers human IgE antibodies into therapeutic IgG antibodies. The lead product is IGNX001, a first-in-class IgG4 monoclonal antibody therapeutic for peanut allergy currently completing Phase 1 clinical trials (ACCELERATE Peanut Study). The pipeline includes additional food allergy programs, an atopic dermatitis program, and research into Alpha-gal Syndrome. The company targets both pediatric and adult patients across food and environmental allergies including peanut, egg, fish, milk, sesame, shellfish, soy, tree nuts, wheat, cat, dog, dust, mold, and pollen allergens.
Differentiator
Problem solved
Functional benefit
Products and services
- IGNX001 A first-in-class, high-affinity, human IgG4 monoclonal antibody therapeutic designed to prevent allergic reactions caused by accidental peanut allergen exposure by blocking the binding of peanut allergens to IgE antibodies. Indicated for adults and adolescents (ages 15-18) with peanut allergy.
- Allergy Program #2 Second food allergy development program in IgGenix's pipeline, currently at 50% completion (Lead Selection stage), targeting an undisclosed allergen.
- Allergy Program #3 Third food allergy development program in IgGenix's pipeline, currently at 25% completion (Lead Selection stage), targeting an undisclosed allergen.
- Atopic Dermatitis Program Development program targeting atopic dermatitis and other atopic/autoimmune conditions where IgE plays a role, currently at 12% completion in discovery stage.
- SEQ SIFTER™ Discovery Platform Proprietary single-cell RNA-sequencing-based antibody discovery platform that captures extremely rare human B cells producing IgE antibodies directly from human blood, then isolates and re-engineers them into fully human, high-affinity, allergen-specific IgG4 antibodies designed to block and prevent the allergic cascade. Foundation of IgGenix's pipeline.
Quantifiable outcome
- Phase 1 ACCELERATE Peanut trial enrolled approximately 24 participants with peanut allergy, with enrollment completed in September 2025
- +4 more outcomes
Companies that use IgGenix
Customer profileSegments4 records
Ideal customer profiles2 records
IgGenix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
IgGenix partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- CZ Biohub SF, LLCcorePatent No. 11,613,569 is exclusively licensed from CZ Biohub SF, LLC and serves as the foundation for IgGenix's proprietary SEQ SIFTER™ platform. This exclusive license enables IgGenix to commercialize technology developed from foundational research at Stanford University.
- Lilly Gateway LabscoreIgGenix moved its headquarters to Lilly Gateway Labs in South San Francisco, a shared innovation laboratory operated by Eli Lilly and Company. This collaboration offers potential access to Lilly scientists, team members and executives, as well as scientific and functional expertise. Companies may collaborate with Lilly on projects of mutual interest, participate in shared learning forums, and potentially receive financial investment from Lilly and their venture network.
Scale indicators10 records
Recent moves7 records
Expansion highlights5 records
IgGenix competitors and assessment
Company assessmentEmerging players
- Prota Therapeutics: Prota Therapeutics is an early-stage food allergy immunotherapy company developing peanut oral immunotherapy approaches. It is a stage-comparable peer in food allergy therapeutics.
- Mabylon AG: Mabylon AG is a Swiss biotech developing human antibody therapeutics for allergies and inflammatory diseases. It is a peer to IgGenix in therapeutic antibody approaches to allergy.
- AnaptysBio: AnaptysBio is a clinical-stage antibody company developing inflammatory and immunology therapeutics. It shares IgGenix's therapeutic antibody development approach and inflammation/immunology focus, though targeting different indications.
- Arcutis Biotherapeutics: Arcutis Biotherapeutics is a commercial-stage company focused on immuno-dermatology, including atopic dermatitis, overlapping with IgGenix's atopic dermatitis program indication.
Direct peers
- Alladapt Immunotherapeutics: Alladapt is a clinical-stage food allergy immunotherapy company developing a multi-food oral immunotherapy for peanut plus other allergens. It targets the same patient population as IgGenix with a similar stage of development.
- Allergy Therapeutics: Allergy Therapeutics is a commercial-stage allergy immunotherapy company developing both subcutaneous and novel short-course allergy immunotherapies across multiple allergens. It is a peer in the broader allergy immunotherapy category.
- DBV Technologies: DBV Technologies is developing Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. It competes head-to-head in the peanut allergy therapeutic space where IgGenix's IGNX001 is positioned.
- Aimmune Therapeutics: Aimmune Therapeutics developed Palforzia, the first FDA-approved oral immunotherapy (OIT) for peanut allergy, now owned by Nestlé Health Science. It is the most direct competitor in peanut allergy therapeutics and a benchmark for IgGenix's lead indication.
Broad incumbents
- Sanofi: Sanofi is Regeneron's Dupixent partner and a major immunology/inflammation pharma incumbent with broad allergy, asthma, and atopic dermatitis franchises. It is a broad incumbent and a potential strategic acquirer of IgGenix.
- Regeneron Pharmaceuticals: Regeneron co-developed Dupixent (dupilumab), a leading immunology biologic approved across multiple allergic and atopic indications including atopic dermatitis. It is a broad incumbent whose franchises overlap with IgGenix's eventual commercial space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
IgGenix social profiles
Digital presenceIgGenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
IgGenix leadership team
Management profileNumber of profiles
Profiles12 records
IgGenix funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IgGenix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IgGenix
What does IgGenix do?
IgGenix is a clinical-stage biotechnology company developing antibody therapeutics for allergic diseases. Using its proprietary SEQ SIFTER™ single-cell RNA-sequencing platform, the company isolates rare human IgE-producing B cells and re-engineers them into high-affinity, allergen-specific IgG4 monoclonal antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and is currently in Phase 1 clinical trials.
Is IgGenix a public or private company?
IgGenix is a private company. It is classified as venture growth investor backed and is currently operating.
When was IgGenix founded?
IgGenix was founded in 2019. It employs 1 to 10 people.
Where is IgGenix based?
IgGenix is headquartered in San Francisco, United States, in the North America region.
How does IgGenix make money?
One revenue line is on record: therapeutic Drug Development and Commercialization.
Who are IgGenix's main competitors?
Emerging players on record are Prota Therapeutics, Mabylon AG, AnaptysBio and Arcutis Biotherapeutics. Direct peers are Alladapt Immunotherapeutics, Allergy Therapeutics, DBV Technologies and Aimmune Therapeutics. Broad incumbents are Sanofi and Regeneron Pharmaceuticals.
Does IgGenix have an API?
No public API is recorded for IgGenix.
What industry is IgGenix in?
IgGenix's product category is Allergy Biologics / Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection).